Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Mutat Res Genet Toxicol Environ Mutagen ; 757(2): 167-72, 2013 Oct 09.
Artigo em Inglês | MEDLINE | ID: mdl-23973768

RESUMO

We investigated whether combinations of ascorbic acid (AA) plus dietary polyphenols can protect in vivo against genotoxic damage induced by endogenous nitrosation. A nitrosation reaction mixture consisting of methylurea (MU) plus sodium nitrite (SN), which can react to form N-nitroso-N-methylurea in the stomach, was administered orally to mice, together with AA and one of the dietary polyphenols ferulic acid (FA), gallic acid (GA), chlorogenic acid (CA), or epigallocatechin gallate (EGCG). Genotoxic damage in bone marrow cells was assessed by measuring micronucleated polychromatic erythrocytes (Mn PCEs) and metaphase chromosome aberrations. When compared to damage induced by MU plus SN alone, co-administration with AA, FA, GA, CA, or EGCG resulted in significant protective effects. Combinations of AA plus EGCG or AA plus CA showed a further protective effect. Reduction in the frequency of Mn PCEs to the control level was obtained following co-administration of a combination of AA, FA, GA, and CA with MU plus SN. A similar trend was observed for metaphase chromosome aberrations. Co-administration of AA, FA, GA, or CA with N-nitroso-N-methylurea (MNU) did not show any significant reduction in genotoxicity, indicating the absence of a protective effect against a preformed N-nitroso compound. Our work demonstrates the protective effects of the 'antinitrosating' combination of AA and dietary polyphenols FA, GA, or CA against genotoxic damage induced by an endogenously formed N-nitroso compound.


Assuntos
Antioxidantes/farmacologia , Ácido Ascórbico/farmacologia , Aberrações Cromossômicas/efeitos dos fármacos , Dano ao DNA , Suplementos Nutricionais , Polifenóis/farmacologia , Animais , Células da Medula Óssea/metabolismo , Células da Medula Óssea/patologia , Eritroblastos/metabolismo , Eritroblastos/patologia , Masculino , Camundongos , Micronúcleos com Defeito Cromossômico , Nitrosação/efeitos dos fármacos , Compostos Nitrosos/metabolismo
2.
Am J Chin Med ; 37(4): 747-57, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19655412

RESUMO

Ginseng is a commonly used herbal medicine with a wide range of therapeutic benefits. Total saponins of Panax ginseng (TSPG) is one of the main effective components of ginseng. Our previous studies have shown that TSPG could promote the production of normal blood cells and inhibition of the leukemia cell proliferation. However, whether ginseng can induce the differentiation of leukemia cells is still unclear. This study was to examine the effect of TSPG or the combination of erythropoietin (EPO) and TSPG on the erythroid differentiation of K562 cells, and their corresponding mechanisms regarding erythropoietin receptor (EPOR) expression. Under light and electron microscopes, the TSPG- or TSPG + EPO-treated K562 cells showed a tendency to undergo erythroid differentiation; early and intermediate erythroblast-like cells were observed. Hemoglobin and HIR2 expressions were significantly increased. As determined by Western blotting analysis, the EPOR protein level in the K562 cytoplasmic membrane was significantly decreased after TSPG treatment, while its cytoplasm level increased in a dose-dependent manner. However, the total cellular EPOR level was unchanged. These results indicate that TSPG-induced erythroid differentiation of K562 cells may be accompanied by the internalization of EPOR. Thus, our study suggests that treatment with a combination of TSPG and EPO may induce erythroid differentiation of K562 cells at least in part through induction of EPOR internalization.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Endocitose/efeitos dos fármacos , Panax/química , Receptores da Eritropoetina/metabolismo , Saponinas/farmacologia , Western Blotting , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , Núcleo Celular/ultraestrutura , Tamanho Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Eritroblastos/efeitos dos fármacos , Eritroblastos/patologia , Eritroblastos/ultraestrutura , Eritropoetina/farmacologia , Citometria de Fluxo , Hemoglobinas/metabolismo , Humanos , Imuno-Histoquímica , Células K562 , Microscopia Eletrônica de Transmissão
3.
Ecotoxicol Environ Saf ; 68(1): 63-70, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16904744

RESUMO

The efficacy of 0.02% vitamin C (VC; l-ascorbic acid) and 0.05% beta-carotene (BC) at the rate of 1 ml/100g of body weight in amelioration of ethyl methane sulphonate (EMS)-induced genotoxicity has been studied in an Indian endemic fish, Anabas testudineus by using several cytogenetical endpoints like chromosome aberrations, micronuclei (MN) and abnormal nuclei (AN), and sperm head anomaly at 6, 24, 48, 72 and 96 h after treatment, as compared to suitable controls (distilled water (DW)-treated control for EMS and VC-treated fish, and 1% alcohol-treated control for BC-treated fish). Both VC and BC reduced EMS-induced genotoxicity at all the fixation intervals as compared to their respective controls. Additionally, effects of two more doses of VC (0.01% and 0.05%) and BC (0.02% and 0.1%) were analyzed at 72 h after treatment (at the peak period of EMS genotoxicity) for testing their relative efficacy in amelioration of EMS-induced cytogenetical damage in this fish. All the three doses of both VC and BC appeared to reduce the EMS-induced genotoxicity in this fish to a variable extent, of which the higher dose of VC appeared to give marginally better protection while the dose-response relationship was inconclusive for BC. The results of this study can lead to future research for exploring if low doses of these vitamins may be useful in protecting fish from genotoxic damage on exposure to mutagenic agents in small confined/stagnant waters.


Assuntos
Antimutagênicos/administração & dosagem , Ácido Ascórbico/administração & dosagem , Metanossulfonato de Etila/toxicidade , Mutagênicos/toxicidade , Percas/fisiologia , beta Caroteno/administração & dosagem , Animais , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/patologia , Aberrações Cromossômicas/induzido quimicamente , Aberrações Cromossômicas/efeitos dos fármacos , Suplementos Nutricionais , Relação Dose-Resposta a Droga , Eritroblastos/efeitos dos fármacos , Eritroblastos/patologia , Eritrócitos Anormais/efeitos dos fármacos , Eritrócitos Anormais/patologia , Masculino , Micronúcleos com Defeito Cromossômico/induzido quimicamente , Micronúcleos com Defeito Cromossômico/efeitos dos fármacos , Testes para Micronúcleos , Espermatozoides/efeitos dos fármacos , Espermatozoides/patologia
4.
Transfusion ; 46(3): 339-47, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16533274

RESUMO

BACKGROUND: Hemoglobin-vesicles (HbVs; diameter, 251 +/- 81 nm) are artificial O(2) carriers. Their efficacy for acute exchange transfusion has been characterized in animal models. However subsequent profiles of recovery involving the degradation of HbV in the reticuloendothelial system (RES) and hematopoiesis remain unknown. STUDY DESIGN AND METHODS: Isovolemic 40 percent exchange transfusion was performed in 60 male Wistar rats with HbV suspended in 5 g per dL recombinant human serum albumin (rHSA; HbV/rHSA, [Hb] = 8.6 g/dL), stored rat RBCs suspended in rHSA (sRBC/rHSA), or rHSA alone. Hematological and plasma biochemical analyses and histopathological examination focusing on the spleen were conducted for the subsequent 14 days. RESULTS: The reduced hematocrit (Hct) level (26%) for the HbV/rHSA and rHSA groups returned to its original level (43%) in 7 days. Plasma erythropoietin was elevated in all groups: the rHSA group showed the highest value on Day 1 (321 +/- 123 mIU/mL) relating to the anemic conditions (HbV/rHSA, 153 +/- 22; sRBC/rHSA, 63 +/- 7; baseline, 21 +/- 3). Simultaneously, splenomegaly occurred in all the groups as HbV/rHSA > rHSA > sRBC/rHSA. Histopathologically, the accumulated HbV in the spleen was undetectable by Day 14, but hemosiderin was deposited in slight quantities for both the HbV/rHSA and sRBC/rHSA groups. Considerable amounts of erythroblasts were apparent in the spleens of both the rHSA and the HbV/rHSA groups. CONCLUSION: HbVs were phagocytized and degraded in RES, a physiological compartment for the degradation of RBCs, and the elevated erythropoietic activity resulted in the complete recovery of Hct within 7 days in the rat model.


Assuntos
Substitutos Sanguíneos , Eritropoese/efeitos dos fármacos , Transfusão Total , Hemoglobinas , Albumina Sérica/química , Animais , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/efeitos adversos , Substitutos Sanguíneos/química , Avaliação Pré-Clínica de Medicamentos , Eritroblastos/patologia , Hematócrito , Hemoglobinas/administração & dosagem , Hemoglobinas/efeitos adversos , Hemoglobinas/química , Humanos , Sistema Fagocitário Mononuclear/efeitos dos fármacos , Sistema Fagocitário Mononuclear/patologia , Ratos , Ratos Wistar , Albumina Sérica/administração & dosagem , Baço/efeitos dos fármacos , Baço/patologia
5.
Sci Total Environ ; 364(1-3): 200-14, 2006 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-16169061

RESUMO

Neem (Azadirachta indica), an indigenous plant commonly grown in India and its sub-continent is a multipurpose plant well known for its insecticidal and biomedical properties, however, its antimutagenic effects in vertebrate organisms are lacking. The present work is therefore, focused on possible antimutagenic potential of ethanolic extract of neem leaves evaluated on the clastogenicity induced by Pentachlorophenol (PCP) and 2, 4-dichlorophenoxyacetic acid (2,4-D) in freshwater fish, Channa punctatus used as a vertebrate model, by cytogenetic endpoints: chromosome aberration (CA) and micronucleus (MN) test. In the first set of experiment, fish were exposed by medium treatment to a single treatment of each chemical (PCP, 0.6 ppm; 2,4-D, 75 ppm; neem extract, 3 ppm) along with the controls. The chromosome preparations were made after processing kidney cells and micronucleus slides were prepared from peripheral blood at multiple duration (48, 72 and 96 h). PCP and 2,4-D when used alone, induced significant CA and MN in a time dependent manner. Neem extract did not show genotoxic potential in both assays. The maximum frequency of CA were recorded as 18.58% and 15.17%, while frequency of MN reached to 8.08% and 4.62% by PCP and 2,4-D respectively, after 96 h exposure. In the second set of experiment, three concentrations of neem extract (1, 2 and 3 ppm) were run simultaneously with the same concentration of PCP (0.6 ppm) and 2,4-D (75 ppm) for antimutagenicity estimates. In mixed treatment, neem extract significantly reduced the frequency of CA and MN. The reduction in the frequency of CA ranged from 40-75% and 45.4-83.3% and similar values for MN were 40.2-75.3% and 44.1-65.8% for PCP and 2,4-D respectively. Although the reductions were significant but not dependent on concentration and time intervals employed. Results suggested that under present experimental conditions, neem extract exhibit strong antimutagenic activity in this fish model, which could further contribute to study its benefit in humans.


Assuntos
Antimutagênicos/farmacologia , Azadirachta , Aberrações Cromossômicas/efeitos dos fármacos , Micronúcleos com Defeito Cromossômico/efeitos dos fármacos , Perciformes/genética , Plantas Medicinais , Ácido 2,4-Diclorofenoxiacético/toxicidade , Animais , Relação Dose-Resposta a Droga , Eritroblastos/efeitos dos fármacos , Eritroblastos/patologia , Água Doce , Rim/efeitos dos fármacos , Rim/patologia , Micronúcleos com Defeito Cromossômico/induzido quimicamente , Testes para Micronúcleos , Modelos Animais , Mutagênicos/toxicidade , Pentaclorofenol/toxicidade , Extratos Vegetais/farmacologia , Folhas de Planta/química
6.
FEBS Lett ; 454(3): 331-4, 1999 Jul 09.
Artigo em Inglês | MEDLINE | ID: mdl-10431833

RESUMO

At subtoxic concentrations, aclacinomycin is effective in controlling erythroid differentiation of K562, a human erythroleukemic cell line. To better understand early events implicated in this process, we have used bisindolylmaleimide (GF109203X), an inhibitor with a high selectivity for protein kinase C (PKC). Our data show that GF109203X inhibits aclacinomycin effects on K562, evidenced by a strong reduction of hemoglobinized cells and a marked decrease of mRNA rates of erythroid genes. To establish firmly PKC involvement, we also verified that aclacinomycin stimulates its rapid translocation, from the cytosolic to the membrane compartment. By Western blot analysis, we also show that after short induction times, PKCalpha was the most implicated.


Assuntos
Aclarubicina/análogos & derivados , Adjuvantes Imunológicos/farmacologia , Eritroblastos/fisiologia , Proteína Quinase C/fisiologia , Transdução de Sinais/efeitos dos fármacos , Aclarubicina/farmacologia , Diferenciação Celular/efeitos dos fármacos , Ativação Enzimática , Inibidores Enzimáticos/farmacologia , Eritroblastos/patologia , Humanos , Indóis/farmacologia , Células K562 , Maleimidas/farmacologia , Proteína Quinase C/antagonistas & inibidores
7.
Br J Haematol ; 31(1): 77-85, 1975 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-764853

RESUMO

Fifty-three patients with megaloblastic anaemia treated with cyanocobalamin and folic acid have been studied. Repeat marrow examination was found to be of value in assessing response to treatment. The early improvement in marrow morphology in patients with pernicious anaemia was greater with 1000 mug than with 5 mug doses of cyanocobalamin. The effect of folate deficiency in delaying marrow response to cyanocobalamin in patients with pernicious anaemia is described and combined cyanocobalamin and folic acid treatment was found to be more effective than either alone. The response to large doses of cyanocobalamin in folate deficient patients was unrelated to the initial serum vitamin B12 level.


Assuntos
Anemia Macrocítica/tratamento farmacológico , Anemia Megaloblástica/tratamento farmacológico , Eritroblastos/patologia , Eritrócitos/patologia , Vitamina B 12/uso terapêutico , Adulto , Idoso , Anemia Megaloblástica/sangue , Exame de Medula Óssea , Ensaios Clínicos como Assunto , Feminino , Ácido Fólico/sangue , Ácido Fólico/uso terapêutico , Deficiência de Ácido Fólico/tratamento farmacológico , Humanos , Ferro/sangue , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Vitamina B 12/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA